Jordi Remon, MD, PhD, on Aumolertinib Plus Chemotherapy in EGFR-Mutated NSCLC
IASLC WCLC 2025
Jordi Remon, MD, PhD, of Gustave Roussy, was the invited discussant for the phase III ACROSS 2 study (Abstract PL02.06). Dr. Remon describes the effect of the addition of aumolertinib, an oral third-generation EGFR tyrosine kinase inhibitor, to platinum/pemetrexed chemotherapy in patients with non–small cell lung cancer (NSCLC) harboring EGFR sensitizing mutations and concomitant tumor-suppressor gene mutations.
The ASCO Post Staff
John M. Varlotto, MD, presents results from the phase III EA5181 trial (from the ECOG-ACRIN Cancer Research Group), which evaluated concurrent and consolidation durvalumab vs consolidation durvalumab alone for patients with unresectable stage III non–small cell lung cancer (NSCLC) (Abstract PL03.04).
The ASCO Post Staff
Patrick Goodley, MBBChir, MRCP, of Manchester University NHS Foundation Trust, reports results from a study that looked at treatment and survival rates in people aged 75 to 80 years diagnosed with screen-detected lung cancer in two targeted lung cancer screening implementation settings (Abstract PL03.19).
The ASCO Post Staff
David Gerber, MD, of UT Southwestern Medical Center, reviews findings from the phase III E4512 trial, which evaluated the hypothesis that postoperative crizotinib may improve disease-free survival in patients with surgically resected ALK-positive non–small cell lung cancer (NSCLC), based on the drug’s efficacy and regulatory approval in advanced ALK-positive NSCLC (Abstract PL02.18).
The ASCO Post Staff
Alexander Drilon, MD, presents findings from the phase I/II ARROS-1 trial, which investigated the safety and efficacy of zidesamtinib—an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) designed to be highly selective, brain-penetrant, and TRK-sparing—in patients with ROS1 fusion–positive non–small cell lung cancer (NSCLC) who experienced disease progression after previous treatment with a TKI (Abstract PL02.15).
The ASCO Post Staff
Susan C. Scott, MD, of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, presents findings from cohort 5 of the phase II PALOMA-2 trial. The data show that subcutaneous administration of the bispecific monoclonal antibody amivantamab-vmjw every 4 weeks, combined with daily receipt of the EGFR TKI lazertinib orally, resulted in high objective response rates among patients with previously untreated EGFR-mutated advanced non–small cell lung cancer (NSCLC) (Abstract MA08.05).